Background/Aims: Neointimal hyperplasia is responsible for stenosis, which requires corrective vascular surgery, and is also a major morphological feature of many cardiovascular diseases. This hyperplasia involves the endothelial-to-mesenchymal transition (EndMT). We investigated whether integrin β3 can modulate the EndMT, as well as its underlying mechanism. Methods: Integrin β3 was overexpressed or knocked down in human umbilical vein endothelial cells (HUVECs). The expression of endothelial markers and mesenchymal markers was determined by real-time reverse transcription PCR (RT-PCR), immunofluorescence staining, and western blot analysis. Notch signaling pathway components were detected by real-time RT-PCR and western blot analysis. Cell mobility was evaluated by wound-healing, Transwell, and spreading assays. Fibroblast-specific protein 1 (FSP-1) promoter activity was determined by luciferase assay. Results: Transforming growth factor (TGF)-β1 treatment or integrin β3 overexpression significantly promoted the EndMT by downregulating VE-cadherin and CD31 and upregulating smooth muscle actin α and FSP-1 in HUVECs, and by enhancing cell migration. Knockdown of integrin β3 reversed these effects. Notch signaling was activated after TGF-β1 treatment of HUVECs. Knockdown of integrin β3 suppressed TGF-β1-induced Notch activation and expression of the Notch downstream target FSP-1. Conclusion: Integrin β3 may promote the EndMT in HUVECs through activation of the Notch signaling pathway.
Integrin β3 Mediates the Endothelial-toMesenchymal Transition via the Notch Pathway
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Introduction
Neointimal hyperplasia is responsible for stenosis, which requires corrective vascular surgery such as arteriovenous fistula surgery and stent angioplasty, and is also a major morphological feature of many cardiovascular diseases such as atherosclerosis and hypertension [1] . The initiating event in neointimal hyperplasia is endothelial cell (EC) damage. Disruption of the overlying layer of the endothelium exposes the underlying vascular smooth muscle cells (VSMCs) to circulating blood elements, which then activate a cascade of events culminating in neointimal hyperplasia [2] . Neointimal lesions mainly comprise smooth muscle-like cells. The endothelium is a source of smooth muscle-like cells and contributes to neointimal hyperplasia through the endothelial-to-mesenchymal transition (EndMT) [1, 3] . However, little is known about the mechanism regulating this process.
The EndMT is a specific form of the epithelial-to-mesenchymal transformation (EMT) [4] . During the EndMT, ECs lose their endothelial-specific markers, gain mesenchymal markers, lose cell-cell junctions, and acquire invasive and migratory properties. The EndMT is not only critical to embryonic cardiac development [5] , but is also involved in the pathogenesis of many diseases, including neointimal hyperplasia [6] , fibrosis [7] , and cancer [8] . Our previous studies reported that the ECs of the neointima of arteriovenous fistulas (AVFs) in uremic mice or end-stage renal disease (ESRD) patients expressed mesenchymal markers [6] . Others studies have identified that the EndMT occurs in myoendothelial cells in human atherosclerotic plaques. After being exposed to a disturbed flow, ECs undergo the EndMT, which contributes to neointimal hyperplasia and induces their atherogenic differentiation [3] . Atherosclerotic ApoE (-/-) mice exhibit extensive development of the EndMT and increased neointimal formation. Furthermore, patients with coronary atherosclerosis show activation of transforming growth factor β (TGF-β) signaling and the development of the EndMT in atherosclerotic plaques [9] .
The integrin β3 family consists of αIIbβ3 and αvβ3. The former is primarily expressed on platelets, whereas the latter is found in ECs and selective inflammatory cells. Our previous report showed that integrin β3 is expressed in both circulating endothelial progenitor cells and in platelets, influencing EC regeneration and blocking neointimal formation in arteriovenous grafts in mice [10] . However, whether integrin β3 influences the EndMT in neointimal hyperplasia remains unknown.
Our aim was to identify the role of integrin β3 in the process of the EndMT. We assessed the expression of endothelial and mesenchymal markers and determined how these changes are regulated in ECs. Our results showed that integrin β3 can induce the EndMT by activating the Notch pathway. These findings will guide the development of interventional methods to prevent the EndMT and alleviate neointimal hyperplasia.
Materials and Methods

Reagents and antibodies
Fetal bovine serum (FBS) and Lipofectamine 2000 were from Invitrogen (Carlsbad, CA). Recombinant human TGF-β1 and Xt-199 were purchased from Sigma-Aldrich (St. Louis, MO).
Antibodies against Jagged-1 and smooth muscle actin (SMA)-α (rabbit) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), whereas antibodies against N1ICD and RBP-Jκ were from Millipore (Burlington, MA). The FSP-1 antibody was from DAKO (Carpinteria, CA). Antibodies against CD31, integrin β3, and VE-cadherin (mouse) were from Bioworld Technology, Inc. (St. Louis Park, MN). The GAPDH antibody was from Sangon Biotech (Shanghai, China). Antibodies against vimentin were from ZSGB-BIO (Beijing, China). Horseradish peroxidase-conjugated secondary antibody IgGs (anti-rabbit, anti-mouse, and anti-goat) were from Beyotime (Shanghai, China). DyLight 488 goat anti-rabbit IgG (H+L) and DyLight 594 goat anti-mouse IgG (H+L) were from Invitrogen. 
Cell culture
Human umbilical vein endothelial cells (HUVECs) were subcultured in basal RPMI 1640 medium (Hyclone Technologies, Logan, UT) supplemented with 10% FBS at 37°C in a humidified 5% CO 2 atmosphere with the medium replaced every ~48 h. For starvation, ECs were incubated in basal medium.
Human AVF samples
Samples of AVFs from six hemodialysis patients ranging in age from 31 to 86 years were studied. In each case, samples of failed AVFs were collected during the creation of a new AVF with the approval of the Army Medical University Review Board.
Luciferase plasmid construction and transfection
To determine FSP-1 promoter activity, up to 2.1 kb upstream from the transcription start site of the FSP-1 promoter was cloned into a luciferase vector. The Xho I restriction enzyme recognition sites (underlined) were added at the 5′ ends of upstream primers and Hind III restriction enzyme recognition sites (underlined) were added at the 5′ ends of downstream primers (5′-CTC GAG TGA GCC CCC ACG CCT CACT-3′, 5′-AAG CTT GAG AGG GGA AGA ATG GGG-3′). The PCR fragments were cloned into a firefly luciferase vector, pGL4.1-Luc (Promega, Madison, WI). Using Lipofectamine 2000, HUVECs were transfected with plasmids and incubated in serum-free media for 24 h before being treated with TGF-β1 (10 ng/ml) for a further 24 h. pRL-TK was co-transfected into the cells and the level of firefly luciferase activity was normalized to Renilla luciferase activity measured by the dual luciferase system (Promega).
Integrin β3 small interfering RNA design and lentivirus transfection
Integrin β3 small interfering RNA (siRNA) lentivirus was used to examine the function of integrin β3. A third generation of the self-inactivating lentiviral vector pLV-EGFP, which contains eGFP (enhanced green fluorescence protein) and puromycin dual reporter genes, was purchased from Cyagen Inc. (Guangzhou, China). The following siRNAs were designed to target integrin β3: siRNA a, 5′-GATGCAGTGAATTGTACCTAT-3′; siRNA b, 5′-CCACGTCTACCTTCACCAATA-3′; and siRNA c, 5′-GATGACTGTGTCGTCAGATTC-3′. A scrambled sequence (5′-CCTAAGGTTAAGTCGCCCTCG-3′) was used as a negative control (Scr) lentivirus. The sequences were cloned into the pLV-EGFP (Cyagen Inc.) to generate the lentiviral vectors.
HUVECs were inoculated in a 12-well culture plate (1 × 10 5 cells/well). Subsequently, lentivirus and polybrene (8 µg/ml) were added to each well. The transfection efficiency was checked by GFP and cells were selected with puromycin (1 µg/ml). Stable cell lines were established after a 1-week selection. The expression of relevant proteins was examined by western blot analysis.
Plasmids and transfection
The pcDNA3.1-beta3 plasmid, which contains human full-length integrin β3 cDNA, was purchased from Addgene (Cambridge, MA). HUVECs were inoculated in a 6-well culture plate (2 × 10 6 cells/well), then cells were transfected with 2 μg plasmid pcDNA3.1-beta3 or pcDNA3.1 using Lipofectamine 2000 according to the manufacturer's instructions. After 24 h transfection, cells were incubated in basal RPMI 1640 medium (Hyclone Technologies) supplemented with 10% FBS for 48 h and the expression of integrin β3 was measured by western blot.
Real-time reverse transcription PCR
Total RNA was isolated using TRIzol reagent (Promega). One microgram of total RNA per sample was then reverse-transcribed into cDNA in a 20-µl volume including 20 U AMV (Takara Bio, Inc., Kusatsu, Japan) according to the manufacturer's protocol. Real-time reverse transcription PCR (RT-PCR) amplification was performed with SYBR Green Master Mix (Bio-Rad Laboratories, Hercules, CA) in a StepOne PCR amplifier (BioRad Laboratories). Untreated cells were used as the reference sample and GAPDH was used as the endogenous control. 
Table 1. Primers used for real-time RT-PCR
Primer Forward Reverse Integrin β3 5'-AGACACTCCCACTTGGCATC-3' 5'-TCCTCAGGAAAGGTCCAATG-3' VE-cadherin 5'-ATCCATTGTGTGCAAGCCACA-3' 5'-CCGTGGTGTTATGTCCTTGTC-3' SMA-α 5'-CAAGTGATCACCATCGGAAATG-3' 5'-GACTCCATCCCGATGAAGGA-3' FSP-1 5'-GGTGTCCACCTTCCACAAGT-3' 5'-GCTGTCCAAGTTGCTCATCA-3' Hes-5 5'-ACATCCTGGAGATGGCTGTC-3' 5'-TAGTCCTGGTGCAGGCTCTT-3' TGF-β1 5'-GCTCCACGGAGAAGAACTGCT-3' 5'-CTGCTCCACCTTGGGCTTGC-3' GAPDH 5'-CGACCACTTTGTCAAGCTCA-3' 5'-AGGGGTCTACATGGCAACTG-3'
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The primers used for the amplification reaction are summarized in Table 1 . Gene expression levels were normalized with GAPDH, and data were analyzed with StepOne software (Applied Biosystems, Foster City, CA). The assay was performed in triplicate, and each experiment was repeated at least three times.
Western blot analysis
After the corresponding treatment, cell extracts were prepared in RIPA buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate). Protein concentration was determined by BCA Reagent (Thermo Fisher Scientific, Waltham, MA). About 30 μg protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After being transferred to a nitrocellulose membrane (Bio-Rad Laboratories), membranes were blocked in blocking buffer at room temperature for 2 h, then incubated overnight at 4°C with primary antibody, followed by horseradish peroxidase-conjugated secondary antibody IgG (anti-mouse, anti-rabbit, or anti-goat) for 2 h at room temperature. Signals were visualized by an enhanced chemiluminescence system (Thermo Fisher Scientific). GAPDH antibody was used as a loading control. The protein bands were visualized using an imaging system (Bio-Rad Laboratories).
Immunofluorescence
Cells were plated on serum-coated coverslips and incubated for the indicated time at 37°C. Thereafter, the cells were fixed and permeabilized by sequential incubation in 4% paraformaldehyde/phosphatebuffered saline (PBS) and 0.5% Triton X-100/PBS for 10 and 5 min, respectively. The actin cytoskeleton was visualized with Alexa 488-conjugated phalloidin (Invitrogen). For the detection of other molecules, after being blocked with blocking buffer (Beyotime), samples were incubated with primary antibody to VEcadherin (1:100), integrin β3 (1:100), or SMA-α (1:300) and then incubated with DyLight 594 or DyLight 488. Nuclear DNA was labeled with DAPI (4′, 6-diamidino-2-phenylindole) (Boster Biological Technology, Pleasanton, CA).
Wound-healing assay
Cells inoculated in 6-well plates were wounded with a 200-µl tip, washed with PBS, and incubated. At different times, photomicrographs were taken to record the migration of HUVECs toward the open area.
Transwell assay
For the Transwell assay, 2 × 10 4 cells were seeded onto the cell insert with an 8-μm pore and incubated in normal RMPI 1640 medium with 2% FBS. Xt-199 was added immediately after cell seeding to the cell insert and the lower chamber. Cells were allowed to migrate for 24 h; non-migrated cells were gently removed with cotton swabs and migrated cells were fixed with methanol and stained with crystal violet. The filters were washed with distilled water and images were obtained under an inverted microscope (Olympus, Hamburg, Germany). Cell numbers were determined and statistically analyzed.
Statistical analysis
Data are expressed as mean ± standard error. Results were analyzed using a t-test when the results from two groups were compared or using two-way analysis of variance when data from over three groups were studied. A p-value < 0.05 was considered statistically significant.
Results
Integrin β3 expression in AVFs
Failed AVFs from patients showed severe neointima hyperplasia (Fig. 1A) . SMA-α was detected in the neointima (Fig. 1B) . Our previous studies confirmed that SMA-α was also expressed in the endothelial layer of AVFs with severe neointima hyperplasia [6] . These results showed that the ECs of AVFs from ESRD patients express the mesenchymal cell marker, SMA-α. We also reported that integrin β3 expression was located in the endothelium and neointima of arteriovenous grafts from patients [10] . Double staining of SMA-α and integrin β3 in AVFs from mice and patients confirmed that SMA-α and integrin β3 were located in the endothelium and the neointima (Fig. 1C and D) . There was increased integrin β3 and TGF-β1 
Integrin β3 regulates the EndMT in HUVECs
When undergoing the EndMT, ECs lose their endothelial-specific markers, such as VEcadherin and CD31, and gain mesenchymal markers, such as SMA-α and FSP-1 [12, 13] . To examine whether integrin β3 affects the EndMT in HUVECs, we examined the change in the expression of the two biomarkers in HUVECs. After transfection of HUVECs with plasmids containing full-length human integrin β3 cDNA, integrin β3 overexpression was confirmed 
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by real-time RT-PCR and western blot ( Fig. 2A and B ). HUVECs transfected with vector were used as a control. In addition, we observed that VE-cadherin was reduced while SMA-α was increased in integrin β3-overexpressing HUVECs compared with vector-transfected control cells ( Fig. 2A and B) . Double staining of VE-cadherin and SMA-α further verified that the overexpression of integrin β3 induced the EndMT of HUVECs (Fig. 2C) .
Knockdown of integrin β3 in ECs suppresses the EndMT
To evaluate the effect of integrin β3 on the EndMT, we used lentivirus-mediated siRNA to knockdown integrin β3 gene expression in HUVECs. The knockdown efficiency of integrin β3 was verified by real-time RT-PCR (Fig. 3A) and western blot (Fig. 3B) . The expression of integrin β3 gene was significantly decreased in HUVECs infected with integrin β3 siRNA (b and c) when compared with cells infected with scrambled siRNA. Because integrin β3 siRNA (c) more efficiently reduced integrin β3 expression than (a) and (b), integrin β3 siRNA (c)-infected HUVECs were used in subsequent experiments. TGF-β can induce integrin β3 expression and the EMT [14] . Therefore, HUVECs were treated with TGF-β1. As shown in Fig.  3C , TGF-β1 treatment significantly enhanced the expression levels of integrin β3, SMA-α, and vimentin in control and Scr-transfected HUVECs, whereas the expression of V--E-cadherin and CD31 was downregulated. After silencing of integrin β3 gene expression in HUVECs, the endothelial markers were increased and mesenchymal markers were reduced (Fig. 3C) . These results indicate that overexpression of integrin β3 promotes the EndMT and that decreased expression of integrin β3 inhibits this process. 
Integrin β3 promotes HUVEC migration and adhesion
ECs change their phenotype through activation of the EndMT program, which enhances cell migration [4] . A wound-healing assay showed that overexpression of integrin β3 in HUVECs or TGF-β1 treatment induced cell migration, which was attenuated by the integrin β3 antagonist Xt199 or by integrin β3 knockdown ( Fig. 4A and E) . A Transwell assay (Fig. 4C  and D) confirmed that the number of migrated cells in the integrin β3-overexpressing group was dramatically increased compared with normal HUVECs (p < 0.05). Cells were incubated on serum-coated coverslips and the cell boundary was visualized with phalloidin staining. As shown in Fig. 4B , HUVECs overexpressing integrin β3 exhibited a well-spread, dish-like morphology compared with control after 30 min plating. Xt-199 suppressed the spreading induced by integrin β3.
Integrin β3 activates the Notch signaling pathway
Notch signaling regulates cell fate determination and differentiation [15] , and activated Notch-1 or -4 can induce the EndMT in cultured ECs [16] . We checked whether the Notch signaling pathway is activated by integrin β3. Notch signaling is initiated by an interaction between Notch receptors and their ligands; the receptor is then cleaved by γ-secretase and the Notch intracellular domain (NICD) is released, which translocates into the nucleus 
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and associates with the DNA-binding protein recombinant binding protein-Jκ (RBP-Jκ) plus coactivators and triggers the expression of target genes. Our results showed that the expression of the Notch ligand Jagged-1 and NICD, the cleaved and activated form of the Notch-1 receptor, was increased in integrin β3-overexpressing HUVECs; TGF-β1 also upregulated NICD expression (Fig. 5B) . However, integrin β3 knockdown inhibited this effect. The expression of the transcription factor RBP-Jκ was not influenced in integrin β3-overexpressing HUVECs, although we detected expression of the Notch target gene Hes-5 in integrin β3 knockdown HUVECs and in TGF-β1-treated HUVECs. The results showed that integrin β3 knockdown significantly inhibited TGF-β1-induced Notch signaling activation.
Integrin β3 regulates FSP-1 expression through the Notch signaling pathway
To examine whether integrin β3-activated Notch signaling affects the EndMT in HUVECs, the expression of FSP-1 and the Notch target genes Hes-5 was detected after the cells were treated with the Notch signaling inhibitor DAPT to block Notch activation. Real-time RT-PCR and western blot showed that there was an increase in the level of Hes-5 and FSP-1 in integrin β3-overexpresing HUVECs. However, the upregulation of Hes-5 was inhibited after DAPT treatment, suggesting that Notch pathway activation was blocked. Although the expression of integrin β3 was not influenced by DAPT, the expression of FSP-1 was downregulated after DAPT treatment (Fig. 6 ). These results suggested that overexpression of integrin β3 activates Notch signaling and increases FSP-1 expression and that inhibition of Notch signaling can suppress the process.
There are RBP-Jκ binding sites in the FSP-1 promoter in mouse smooth muscle cells [17] . To explore whether integrin β3 influences the expression of FSP-1 through activation of Notch signaling, we created a luciferase-reporter construct containing the region 2100 bp upstream of the transcription start site of human FSP-1 promoter. In the absence of FSP-1 promoter sequences, there was no luciferase activity detected with or without TGF-β1 stimulation. However, integrin β3 knockdown suppressed TGF-β1-induced FSP-1 promoter activities by ~70% versus control HUVECs. Taken together, these results indicate that integrin β3 increases FSP-1 expression by activating Notch signaling.
Discussion
Neointimal formation is an exaggerated healing process that occurs in the vessel wall after injury. ECs play vital roles in the process of neointimal hyperplasia. The damage to ECs initiates the development of neointimal hyperplasia and endothelial regeneration occurs to restore the protective barrier at the end of the neointimal hyperplasia [18] . In addition, VSMC proliferation and migration are common characteristics of neointimal hyperplasia; ECs also contribute to neointimal hyperplasia as a source of smooth muscle-like cells [1] . We and others have previously shown that ECs can acquire a fibro-proliferative mesenchymal phenotype through the EndMT under pathological conditions [3, 6] . Our present data showed that TGF-β1-induced integrin β3 expression can modulate the EndMT by promoting mesenchymal marker expression in a Notch-dependent manner.
Integrins are transmembrane heterodimeric glycoprotein receptors consisting of α and β subunits that are crucial for modulating fundamental cell processes and functions including cell adhesion, proliferation, migration, and survival. Circulating endothelial progenitor cells deficient in integrin β3 show impaired adhesion activity toward exposed subendothelium, fail to differentiate into mature ECs, and promote neointimal formation at arteriovenous graft sites [10] . However, integrin αvβ3 arginine-glycine-aspartic acid (RGD) antagonists have been used to reduce neointimal hyperplasia, mainly by blocking VSMC accumulation [19] . Here, the severe neointima hyperplasia of patients showed significant integrin β3 expression (Fig. 1) . Our in vitro experiments showed that HUVECs overexpressing integrin β3 exhibited smooth muscle-like cell phenotypes ( Fig. 2 and 3 [20] and fibrosis [21] . Recent work showed that RGD antagonists that interact with integrin αvβ3 could revert the TGF-β1-induced EndMT in endothelial precursor cells [22] . These previous studies indicated that integrin β3 may play an important role in endothelial transdifferentiation. We found that AVF patients had high integrin β3 and TGF-β1 expression at areas of anastomosis (Fig. 1) . TGF-β1 itself is a growth factor and a potent inducer of the EndMT. Not only TGF-β1, but also overexpression of integrin β3 in HUVECs promoted the EndMT. Because TGF-β1 induces integrin β3 expression and knockdown of integrin β3 inhibits the TGF-β1-induced EndMT (Fig. 2-4) , this evidence reveals that TGF-β1 possibly mediates the EndMT by regulating integrin β3 expression.
As a major regulator of cell phenotype, Notch is involved in the process of the EndMT. Mammals express four Notch transmembrane receptors (Notch-1, Notch-2, Notch-3, and Notch-4) and five typical transmembrane ligands (Delta-like 1 [Dll-1], Dll-3, Dll-4, Jagged-1, and Jagged-2). As mentioned, different combinations of Notch receptors and their ligands can play different roles in EC behavior [1] . Noseda et al. [16] provided the first evidence that Notch activation in ECs results in morphological, phenotypic, and functional changes and induces the EndMT. Because Notch-1 is the primary functional Notch receptor during developmental angiogenesis [23] , we assessed Notch-1 activation to analyze the mechanism of integrin β3 in the EndMT. Notch1 activation is clearly observed in TGF-β1-treated HUVECs and in integrin β3-overexpressing HUVECs through upregulation of Notch-1 cleavage and target gene Hes-5 expression (Fig. 5 and 6 ). In addition, the Notch inhibitor DAPT inhibited Hes-5 expression but had no effect on integrin β3 expression (Fig. 6) . Thus, these results proved that integrin β3 is an upstream regulator of the Notch signaling pathway. Because integrin regulates cell adhesion and migration, the signal transduction of the Notch signaling pathway is limited between cells that are in contact with each other. Our data showed that overexpressed integrin β3 induced the EndMT through activation of the Notch signaling pathway. Elevated Notch signaling upregulates mesenchymal marker expression in ECs and leads to endothelial barrier dysfunction in AVFs [6] . Our findings explained the mechanism of neointimal formation in vascular disease regulated by integrin β3. FSP-1 (S100A4, also known as metastasin) is a member of the S100 family of calcium-binding proteins. It was isolated from mouse mammary adenocarcinoma cells, and its mRNA is detectable in cells of the bone marrow, spleen, and thymus and in lymphocytes [24] . FSP-1 regulates cellular motility through a direct interaction with myosin-IIA [25] ; FSP-1 is also associated with cancer cell metastasis [20] , including the invasive growth of mouse ECs [26] or neurons [27] . FSP-1 can play a role in vascular remodeling. We previously identified that secreted FSP-1 influences the proliferation of VSMCs in arteriovenous grafts [28] and that knockout of FSP-1 suppresses VSMC migration and ameliorates neointimal formation [17] . According to our data, overexpression of integrin β3 promotes the expression of FSP-1 in HUVECs by activating the Notch pathway and inducing transcription factor binding to the FSP-1 promoter (Fig. 6) . Increased expression of FSP-1 in ECs leads to EC barrier dysfunction, the EndMT, and cell migration.
Conclusion
We found that the TGF-β1-induced expression of integrin β3 promotes the EndMT. During this process, integrin β3 induces FSP-1 promoter activity and enhances FSP-1 expression via activation of the Notch signaling pathway. In this way, ECs acquire smooth muscle-like cell pheonotypes and enhanced cell migration ability. Our findings identify a novel vascular protective mechanism of integrin and suggest that inhibition of the EndMT might provide a novel therapeutic strategy to suppress neointimal hyperplasia in vascular disease.
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